UPDATED: Merck's pause on an HIV program snowballs as a Gilead-partnered trial is shoved into limbo
Merck’s announcement last week that an experimental HIV combo therapy resulted in a drop in immune cell counts, and its subsequent decision to halt a Phase II study, is starting to see a snowball effect.
Late Tuesday afternoon, the pharma giant and partner Gilead said they are pausing enrollment of a separate study using one of the investigational compounds from Merck’s solo trial. The move was made “out of an abundance of caution” after Merck stopped the other study, the companies said, allowing investigators to consider potential modifications.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.